TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.14B | $3.98B | $1.50B | $4.48B | $4.18B | $3.89B | $4.23B | $4.33B |
| Cost of Revenue | $1.99B | $2.01B | $2.06B | $2.18B | $2.07B | $2.01B | $2.11B | $2.18B |
| Gross Profit | $2.15B | $1.97B | $2.66B | $2.30B | $2.10B | $1.88B | $2.12B | $2.15B |
| Gross Margin | 52.0% | 49.5% | 177.0% | 51.4% | 50.3% | 48.2% | 50.2% | 49.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $317.0M | $304.0M | $368.0M | $317.0M | $305.0M | $297.0M | $302.0M | $298.0M |
| Operating Income | $-231.0M | $652.0M | $301.0M | $882.0M | $455.0M | $519.0M | $-29.0M | $-51.0M |
| Operating Margin | -5.6% | 16.4% | 20.1% | 19.7% | 10.9% | 13.3% | -0.7% | -1.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-455.0M | $437.0M | $80.0M | $646.0M | $203.0M | $294.0M | $-247.0M | $-324.0M |
| Income Tax Expense | $121.0M | $67.0M | $-390.0M | $214.0M | $-78.0M | $74.0M | $29.0M | $69.0M |
| Net Income | $-576.0M | $369.0M | $481.0M | $433.0M | $282.0M | $214.0M | $-217.0M | $-437.0M |
| Net Margin | -13.9% | 9.3% | 32.1% | 9.7% | 6.8% | 5.5% | -5.1% | -10.1% |
| EPS (Basic) | $-0.49 | $0.32 | $0.41 | $0.38 | $0.25 | $0.19 | $-0.19 | $-0.39 |
| EPS (Diluted) | $-0.49 | $0.31 | $0.42 | $0.37 | $0.24 | $0.18 | $-0.19 | $-0.39 |
| Shares Outstanding (Basic) | 1.17B | 1.16B | 1.15B | 1.15B | 1.15B | 1.14B | 1.13B | 1.13B |
| Shares Outstanding (Diluted) | 1.17B | 1.18B | 1.16B | 1.16B | 1.16B | 1.16B | 1.13B | 1.13B |
| Dividends Per Share | — | — | — | — | — | — | — | — |